NAVAMEDIC ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34 NOK | -0.29% |
|
-0.29% | -7.36% |
| Sales 2023 | 512M 46.44M 3.71B | Sales 2024 * | 609M 55.21M 4.42B | Capitalization | 593M 53.76M 4.3B |
|---|---|---|---|---|---|
| Net income 2023 | 3M 272K 21.77M | Net income 2024 * | 40M 3.63M 290M | EV / Sales 2023 | 1.46 x |
| Net Debt 2023 | 109M 9.84M 787M | Net Debt 2024 * | 40M 3.63M 290M | EV / Sales 2024 * | 1.04 x |
| P/E ratio 2023 * |
40.2
x | P/E ratio 2024 * |
15
x | Employees | 45 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 58.33% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.29% | ||
| 1 week | -0.29% | ||
| Current month | -4.49% | ||
| 1 month | -5.29% | ||
| 3 months | -9.09% | ||
| 6 months | -8.11% | ||
| Current year | -7.36% |
1 week
33.60
34.70
1 month
32.9037.30
Current year
32.6040.00
1 year
31.0043.90
3 years
19.5043.90
5 years
13.5043.90
10 years
8.0043.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 31/05/18 | |
Lars Hjarrand
DFI | Director of Finance/CFO | 51 | 08/12/19 |
| Chief Tech/Sci/R&D Officer | - | 31/12/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Narve Reiten
BRD | Director/Board Member | 63 | - |
Terje Bakken
CHM | Chairman | 58 | 30/12/18 |
Jostein Davidsen
BRD | Director/Board Member | 65 | 15/01/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 34 | -0.29% | 4,319 |
| 25/04/24 | 34.1 | -0.29% | 5,724 |
| 24/04/24 | 34.2 | 0.00% | 6,272 |
| 23/04/24 | 34.2 | +0.29% | 2,150 |
| 22/04/24 | 34.1 | 0.00% | 14,446 |
Real-time Oslo Bors, April 26, 2024 at 03:45 pm
More quotes
Navamedic ASA is a Norway-based pharmaceutical company. It is a supplier of products delivered to hospitals and pharmacies. Navamedicâs product portfolio consists of prescription and Over The Counter (OTC) pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. The Companyâs offering is divided into four product areas: Consumer Health, Specialty Pharma, Medical Nutrition and Branded Generics. The Company has one business segment which is the Pharma division. Navamedic ASA is present in all Nordic countries, the Baltics and Benelux. The Company has two subsidiaries, Navamedic AB, through which the Company distributes more than 40 products and a Norway-based Novicus Pharma AS.
Sector
Pharmaceuticals
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
34
NOK
Average target price
49
NOK
Spread / Average Target
+44.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.36% | 53.67M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- NAVA Stock
